Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients
BERGEN, Norway, June 11, 2021 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
